# A Phase 1 Comparative Study of E2022 Current and New Patch Formulations

> **NCT02042729** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** E2022- Current Formula Tape
- **DRUG:** E2022- New Formula Tape
- **DRUG:** E2022 Matching Placebo- Current Formula Tape
- **DRUG:** E2022 Matching Placebo- New Formula Tape

## Key facts

- **NCT ID:** NCT02042729
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042729, "A Phase 1 Comparative Study of E2022 Current and New Patch Formulations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02042729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*